4月1日,美国FDA顾问小组推荐批准MannKind公司的吸入型糖尿病药物Afrezza,称这款药物可能会帮助患者,特别是那些对胰岛素注射针头有恐惧心理的患者。FDA顾问小组表示,虽然Afrezza对1型糖尿病成人患者没有表现出收益,但它对更常见的2型糖尿病却是明显安全有效的。顾问小组以13比1的投票结果推荐批准这款药物用于1型糖尿病患者,一致投票支持其用于2型糖尿病患者,并补充称,这款药物仍需进行更长期的研究,以监测可能的不良作用。顾问小组的推荐为这款口哨 On April 1, the US FDA advisory panel recommended approval of MannKind's inhaled diabetes drug Afrezza, saying the drug may help patients, especially those with fear of insulin needles. The FDA advisory panel said that while Afrezza shows no benefit for adults with type 1 diabetes, it is clearly safe and effective for the more common type 2 diabetes. The advisory panel, which recommended approval of the drug for type 1 diabetes on a 13-to-1 vote, unanimously voted in favor of its use in patients with type 2 diabetes, adding that the drug still needs more long-term studies to detect possible The adverse effects. The advisory panel recommended this whistle